|Previous Section||Index||Home Page|
Jane Kennedy: The Healthcare Commission's latest programme of clinical audits, is shown in the following table. Some of the Healthcare Commission's latest programmes have yet to start. For current clinical audits information is provided on the latest, and where appropriate, next expected publication.
|Last report||Next report||Type|
|CancerBowel cancer (NBOCAP)||June 2005||July 2006||Findings|
|Head and neck cancer (DAHNO)||n/a||March 2006||Early findings|
|Lung cancer (LUCADA)||n/a||March 2006||Early findings|
|Oesophago-gastric (stomach) cancer||n/a||April 2007||Early findings|
|Mastectomy and breast reconstruction||n/a||n/a||Yet to start|
|Child and MaternityNeonatal intensive care||n/a||December 2006||Early findings|
|Maternity care||n/a||March 2006||Scoping report(6)|
|Emergency care, critically ill or injured child||n/a||n/a||Yet to start|
|EmergencyHead injury patients||n/a||n/a||Yet to start|
|Severely injured patients||n/a||n/a||Yet to start|
|HeartAdult cardiac surgery||October 2004||||Public website|
|Paediatric cardiac surgery and interventions||n/a||April 2006||Findings|
|Cardiac interventions (e.g. opening up heart artery)||October 2004||||Not yet fixed|
|Myocardial infarction (MINAP) (heart attack)||June 2005||June 2006||Findings|
|Rhythm management (pacing/implantable defibrillators)||March 2003||December 2005||Findings|
|Heart failure||n/a||n/a||Yet to start|
|Cardiac ambulance services||n/a||||Not yet fixed|
|Cardiac patients' pathway and outcomes||n/a||||Not yet fixed|
|Long-term conditionsDiabetes||September 2005||September 2006||Findings|
|Renal services (kidney disease)||n/a||March 2006||Scoping report(6)|
|Rheumatoid arthritis||March 2005||April 2006||Findings|
|Asthma||n/a||n/a||Yet to start|
|Long-term neurological conditions||n/a||n/a||Yet to start|
|Violence in mental healthMental health settings||May 2005||April 2006||Findings|
|Psychological therapies||n/a||n/a||Yet to start|
|Eating disorders||n/a||n/a||Yet to start|
|Older peopleContinence (NACC)||November 2005||December 2006||Findings|
|Stroke: hospital services||March 2005||March 2007||Findings|
|Carotid endarterectomy (UKCEA) (stroke prevention)||n/a||February 2006||Early findings|
|Services for people who have fallen||n/a||March 2006||Findings|
|Venous leg ulcers||n/a||March 2006||Findings|
|Dignity and care in hospital and other settings||n/a||n/a||Yet to start|
|Stroke: patients' pathway, focussing on primary care||n/a||n/a||Yet to start|
|Patients with co-morbidities in primary care||n/a||n/a||Yet to start|
|Dementia services and prescribing||n/a||n/a||Yet to start|
|Reproductive healthControl of heavy menstrual bleeding||n/a||n/a||Yet to start|
Joan Walley: To ask the Secretary of State for Health if she will meet the North Stoke Primary Care Trust to discuss extra funding for the NHS prescription of Herceptin in this financial year. 
Ms Rosie Winterton: The national health service is already benefiting from the increased investment in the NHS which between 2003 and 2008 will increase on average by 7.5 per cent. each year. It is for primary care trusts (PCTs) to decide on how best to use these resources based on the needs of their local populations. Therefore it would not be appropriate for the Secretary of State or a member of the ministerial team to meet this particular PCT.
We have taken steps to ensure that breast cancer patients who could benefit from Herceptin can be identified and treated. On 5 October we announced that all breast cancer patients would be tested for suitability for treatment with Herceptin. The national cancer director is working with cancer networks to ensure that testing arrangements are in place so that once Herceptin is licensed for early breast cancer those patients who would benefit are quickly identified.
On 3 November, we launched a new rapid process for assessing drugs and other treatments to sit alongside the National Institute for Health and Clinical Excellence's (NICE) global standard process. This new single technology appraisal (STA) will be used to produce faster guidance on life-saving drugs which have been licensed.
Roche, the manufacturer of Herceptin, has announced that its application for a licence will be made to the European medicines agency for the evaluation of medical products in February 2006, with a decision anticipated by July 2006 at the earliest. The new STA will allow NICE to react as soon as possible after the drug is licensed.
Mr. Holloway: To ask the Secretary of State for Health what plans she has to make extra resources available for primary care trusts to fund the provision of Herceptin for women with early stage breast cancer. 
We understand that some trusts are already under financial pressures and may have to make difficult decisions in achieving this. However, we have greatly increased the amount of money going into the NHS and those trusts with deficits have financial recovery plans in place.
Ms Rosie Winterton [holding answer 15 December 2005]: The National Institute for Clinical Excellence guidance on supportive and palliative care, published in 2004, gives recommendations to improve the care provided to people with cancer, including responding to patients' wishes about where they are cared for, and die. The guidance endorses three tools: the gold standards framework, the Liverpool care pathway, and the preferred place of care, which are being rolled out nationally through the end of life care programme and are applicable to the care of people at the end of life, regardless of their condition.
The end of life care programme has been given funding of £12 million over three years (200407), and provides training for staff in acute, community and care home settings so that all patients near the end of life have access to high quality palliative care and are able to choose where they receive care.
Ms Rosie Winterton [holding answer 15 December 2005]: The discharge of terminally ill patients from hospital is based on the clinical decision of the health service staff responsible for that patient's care. Decisions on discharge are informed by the recommendations in the National Institute for Clinical Excellence guidance on supportive and palliative care, published in 2004. The guidance endorses the use of three key tools: the gold standard framework, the Liverpool care pathway and the preferred place of care, which support clinicians and patients to plan how and where services are provided that best meet the wishes of the patient. The national roll-out of these tools is a key part of the end of life care programme, which is a three-year Government programme to provide patients with the choice to die at home.
Stewart Hosie: To ask the Secretary of State for Health what the value is of (a) pay supplements, (b) bonuses and (c) other incentive packages that are payable in her Department on the basis of geographic location; how many people are in receipt of each payment; and what the total cost to her Department of each payment was in 200405. 
|Next Section||Index||Home Page|